Imported Fasciola hepatica infection in the United States and treatment with triclabendazole.
Infection with Fasciola hepatica, a liver trematode, is not frequently reported in the United States. We describe 2 patients, both originally from Cape Verde, who illustrate the spectrum of clinical presentations of F. hepatica as well as the means of treating infection with this parasite. Patient 1 had extensive disease and underwent multiple diagnostic procedures before the correct diagnosis was reached. Patient 2, who had few symptoms, had fascioliasis diagnosed by a noninvasive evaluation. Both patients were treated with triclabendazole without experiencing significant side effects. Fascioliasis that has been imported to the United States may elude prompt or accurate diagnosis. Obtaining a detailed travel history and recognizing the clinical presentation early in the course of infection may permit timely and noninvasive identification of infection. Triclabendazole is now the recommended drug for treating for fascioliasis because of its efficacy, safety, and ease of use.
Graham
C S
CS
Division of Infectious Disease, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. cgraham@caregroup.harvard.edu
Brodie
S B
SB
Weller
P F
PF
D000328:Adult; D000354:Africa, Western; D000368:Aged; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000097:blood; D001562:Benzimidazoles / Q000627:therapeutic use*; D005210:Fasciola hepatica / Q000276:immunology / Q000302:isolation & purification; D005211:Fascioliasis / Q000175:diagnosis* / Q000188:drug therapy* / Q000469:parasitology; D005243:Feces / Q000469:parasitology; D006801:Humans; D008297:Male; D014195:Travel; D000077682:Triclabendazole; D014481:United States
D000871:Anthelmintics; D000909:Antibodies, Helminth; D001562:Benzimidazoles; D000077682:Triclabendazole